ClinicalTrials.gg
Status unknownNCT03401359Updated Jan 17, 2018

The Resistance and Immune Response to Palbociclib in Breast Cancer

An interventional study of tissue biopsy, blood sample in Breast Cancer Stage IV, sponsored by Samsung Medical Center. Status unknown at 1 site in Korea, Republic of. Open to female participants. Per ClinicalTrials.gov, last updated 2018-01-17.

Sponsored by Samsung Medical Center · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Jan 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies in Breast Neoplasms by Samsung Medical Center — 13 open to participants now, 15 under way, 1 of them phase 3. Breast Neoplasms · Samsung Medical Center.

Planned enrollment
17th of 27
100 · median 147
Started
2017
with 1 other
No phase
17 of 46
5 open now
Registered
16th of 46
by date

Among the 46 studies in Breast Neoplasms by Samsung Medical Center, this one is the 17th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2017, is one of 17 with no phase, and was the 16th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 46 studies in Breast Neoplasms by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Breast Neoplasms by Samsung Medical Center, or all of them as a file.
02

Study summary

The investigators propose to conduct a biomarker and molecular profiling study in longitudinally paired tumor biopsies and serum from patients with Hormone Receptor positive (HR+) metastatic Breast Cancer (BC) treated with Palbociclib in combination with endocrine therapies.

Read the detailed description

The investigators propose to conduct a biomarker and molecular profiling study in longitudinally paired tumor biopsies and serum from patients with Hormone Receptor positive (HR+) metastatic Breast Cancer (BC) treated with Palbociclib(Palbo) in combination with endocrine therapies.

The investigators plan to obtain tumor biopsy and blood samples, taken at both pre-treatment and post-progression, from 40 patients who develop acquired resistance to Palbo + endocrine combination treatment. All assays will be conducted in parallel on both pre and post-treatment samples to identify differences that may account for acquired resistance. Cyclin E1 and E2 levels will be assessed by IHC on tumor biopsies. Neuregulin-1 levels will be assessed by ELISA assay on serum. Tumor biopsies will be further profiled using whole-exome sequencing (WES) and whole-transcriptome sequencing (RNA-Seq). Matched blood samples will be subject to WES to facilitate somatic mutation detection. Paired tumor biopsies will undergo immunohistochemistry (IHC) analysis of TIL markers to assess Palbo-induced changes. Finally, we will apply the in-house circulating tumor DNA (ctDNA) assay, which employs a custom-designed panel for studying Palbo acquired resistance, towards the analysis of 40 pairs of plasma samples. The custom ctDNA panel will be extended to include additional mutations identified from this study that confer acquired resistance.

To further evaluate the effects of Palbo treatment on intratumoral TILs, the investigators plan to acquire paired tumor biopsy and matched blood samples, at baseline and two time points (6 weeks, 12 weeks) during the course of Palbo treatment, from 20 patients. And they will select metastatic BC patients who exhibit stable diseases (SD) in response to Palbo for tumor biopsies, prior to knowledge of whether post-progression biopsy would be available. Tumor biopsies will be subject to WES, RNA-Seq and IHC analyses. Further, the investigators plan to quantify the abundance of immune cell sub-populations in the matched blood samples using flow cytometry (FACS) to assess Palbo treatment effects on systematic immunity.

While on-treatment samples can be collected after 6 weeks and 12 weeks of initiating Palbo treatment, it takes about 18 months on average for initially treated patients with late stage HR+ breast cancers to develop acquired resistance. Only an estimated 40% of relapsed cases will have successful biopsies due to a lack of consent or difficult-to-operate biopsies such as bone-only metastases. Hence, the investigators plan to bank pre-treatment biopsies and blood samples from about 100 patients by Q2 2018 in order to collect 40 post-progression biopsies as matched pairs within the 2-year time frame. FFPE slides will be made from all tumor biopsies, including the 100 cases at baseline, and subject to H\&E staining. The investigators will detect and quantify TILs through machine learning and digital imaging analysis of the H\&E data.

03

Conditions studied

  • Breast Cancer Stage IV

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hormone receptor positive, breast cancer
  • Treated by palbociclib with endocrine therapy

Exclusion criteria

Exclusion Criteria:

  • Hormone receptor negative breast cancer
  • Treated without palbociclib
  • Refuse and withdrawal to this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Interventions

  • Genetictissue biopsy, blood sample

    At baseline, 100 tumor/blood samples will be banked. Only \~60 will be profiled if the paired samples are acquired post-progression or on-treatment. On-treatment blood samples will be serially collected and banked from all consenting patients.

This study also gives Palbociclib. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Biomarker of palbociclib in metastatic breast cancer

    Biomarker of acquired resistance and immune response to palbociclib in metastatic breast cancer from whole exome sequencing, RNASeq, circulating tumor DNA and flow cytometry.

    Time frame: 24.8 months (median progression free survival in palbociclib plus letrozole treatment (according to PALOMA-2 trial)

07

Study locations

1 of 1 sites recruiting
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
    Recruiting
    • Yeon Hee Park, MD, Ph.D · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2017 (actual). Primary completion is estimated for Oct 2020, 36 months after the start.

Of 2,664 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 36 months is close to that.

Counting every sponsor, half of 2,774 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2017
First posted
Jan 17, 2018
StartActual
Oct 24, 2017
Primary completionEst.
Oct 31, 2020
CompletionEst.
Oct 31, 2022
Last update
Jan 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03401359
Responsible party
Yeon Hee Park (Professor, Samsung Medical Center) — Principal investigator
First posted
Jan 17, 2018
Start date
Oct 24, 2017
Primary completion
Oct 31, 2020 (estimated)
Completion
Oct 31, 2022 (estimated)
Last update
Jan 17, 2018

Study contacts

Yeon Hee Park, MD
Contact
yhparkhmo@skku.edu
82-2-3410-1780

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion